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Abstract Chronic migraine (CM) represents migraine
natural evolution from its episodic form. It is realized
through a chronicization phase that may require months or
years and varies from patient to patient. The transition to
more frequent attacks pattern is inﬂuenced by lifestyle, life
events,comorbid conditionsand personalgeneticterrain,and
it often leads to acute drugs overuse. Medication overuse
headache (MOH) may complicate every type of headache
and all the drugs employed for headache treatment can cause
MOH. The ﬁrst step in the management of CM complicated
by medication overuse must be the withdrawal of the over-
used drugs and a detoxiﬁcation treatment. The goal is not
only todetoxify the patientandstopthe chronic headachebut
also to improve responsiveness to acute or prophylactic
drugs. Different methods have been suggested: gradual or
abruptwithdrawal; home treatment,hospitalization, ora day-
hospital setting; re-prophylaxes performed immediately or at
the end of the wash-out period. Up to now, only topiramate
and local injection of onabotulinumtoxinA have shown
efﬁcacy as therapeutic agents for re-prophylaxis after
detoxiﬁcation in patients with CM with and without medi-
cation overuse. Although the two treatments showed similar
efﬁcacy, onabotulinumtoxinA is associated with a better
adverse events proﬁle. Recently, the Phase III Research
Evaluating Migraine Prophylaxis Therapy (PREEMPT)
clinical program proved that patients with CM, even those
with MOH, are the ones most likely to beneﬁt from
onabotulinumtoxinA treatment. Furthermore, it provided an
injection paradigm that can be used as a guide for a correct
administration of onabotulinumtoxinA.
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Introduction
Chronic migraine (CM) constitutes migraine natural evo-
lution from its episodic form. It is realized through a
chronicization phase that may require several months or
years and varies from patient to patient. The transition to
more frequent attacks pattern is inﬂuenced by lifestyle, life
events, comorbid conditions and personal genetic terrain,
and it often leads to acute drugs overuse, rather being
accompanied by that.
The International Classiﬁcation of Headache Disorders,
II version revised (ICHD-IIR), includes criteria for CM in
which the disorder is deﬁned by headaches on C15 days/
month for C3 months, of which C8 days fulﬁll the criteria
for migraine without aura which were successfully treated
with acute care medications such as ergots or triptans [1].
Chronic daily headache (CDH) syndromes are a group
of headache disorders that occur on C15 days/month, for
C4 h/day for C3 months. CM, chronic tension-type head-
ache (CTTH), hemicrania continua (HC) and new daily
persistent headache (NDPH) are primary headache disor-
ders, whereas medication overuse headache (MOH) is
classiﬁed in the ICHD-IIR as an ‘‘independent’’ secondary
headache. ICHD-IIR precludes the diagnosis of any of
these headache types, other than MOH, if the patient is
overusing acute medication [1, 2].
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characterized by generation, perpetuation and persistence
of intense chronic migraine caused by the frequent and
excessive use of symptomatic drugs for at least 3 months,
for a certain number of days per month [2]. MOH may
complicate each type of headache and all the drugs
employed for headache treatment can cause MOH.
Classiﬁcation criteria of abuse are related to the phar-
maceutical class applied during acute treatment, namely of
15 days/month for analgesics and non-steroid anti-inﬂam-
matory drugs (NSAID), and 10 days/month for mixed
drugs (triptans, ergotamines, opioids, and NSAID) [3].
Because of their availability and low cost, barbiturate-
containing combination analgesics and over-the-counter
caffeine-containing combination analgesics are the greatest
problem. Even though triptans overuse headache is not
encountered with great frequency, all triptans should be
considered potential inducers of MOH [3].
MOH can be distinguished as simple (MOH Type I) or
complex (MOH Type II). Simple cases involve relatively
short-term drug overuse, relatively modest amounts of
overused medications, minimal psychiatric contribution,
and no history of relapse after drug withdrawal. In contrast,
complex cases often present with multiple psychiatric
comorbidities and a history of relapse [4].
Chronic migraine challenges
The prevalence rate of CM in general population is 2–4%
[5]. Each year, approximately 2.5% of patients with epi-
sodic migraine (EM) develop new-onset CM [6].
At this time, CM represents the most important chal-
lenge for tertiary headache centers, where more than 50%
of patients are referred for monitoring the chronicization
process and its possible complication with MOH.
Compared with patients with EM, those with CM are
female,menopausal,married,unemployed,onpolypharmacy,
not using oral contraceptives, having worse socioeconomic
status, reduced health-related quality of life, increased head-
ache-related burden (including impairment in occupational,
social, and family functioning), migraine remission during
pregnancy, and having greater psychiatric (e.g., depression,
anxiety and chronic pain) and medical comorbidities (e.g.,
hypertension, diabetes, high cholesterol and obesity) [6, 7].
Among patients in headache clinics or centers of tertiary
care, patients with MOH form the largest group along with
migraine and tension-type headache. Up to 30% of patients
in such centers in Europe, and more than 50% in the USA,
present with MOH [8, 9].
MOH affects 1–4% of general population, with preva-
lence rates similar across different countries [10, 11] but
with a higher preponderance in women than in men [11].
It has been noted that the overuse of analgesics for
chronic headache is not only prevalent in Europe and North
America but also presents in Asian countries [12]. More-
over, clinical evidence demonstrates that overuse associ-
ated with chronic forms of headache can occur in
childhood and early adolescence and not only in adults and
elderly patients [13].
Migraine attacks can increase in frequency over time.
Headache experts conceptualize this process with a model
that envisions transition into and out of four distinct states:
no migraine, low-frequency EM (\10 headaches/month),
high-frequency EM (10–14 headaches/month), and CM
(C15 headaches/month) [6]. The transition may be both
in the direction of increasing or decreasing headache
frequency.
Migraine’s chronicization and the subsequent appear-
ance of MOH are realized through a period of time which
involves several months or years. This escalation produces
daily, or almost daily pattern, in some cases with symp-
tomatology less adherent to a classic migraine attack [14].
Thisleadstheheadachetomanifestinadifferentwayfrom
the original headache form since pain can vary according to
severityandlocation.Moreover,theassumptionofpreviously
effective medication could induce or worsen headache.
Roads to migraine chronicization
Patients with an intermediate headache frequency of
6–9 days/month are at greater risk for further progression
to CM. The risk is even greater in patients who have
headaches on 10–14 days/month [15]. For that reason, in
presence of CM’s low prevalence, special attention should
be paid to both control and reduction of risk factors which
might favor the migraine chronicization process and/or the
outbreak of MOH [16].
Risk factors for chronicization can be divided into three
categories: nonmodiﬁable, modiﬁable, and putative.
Nonmodiﬁable risk factors include older age, female
sex, caucasian race, worse socioeconomic status, low
education level [17, 18], and genetic factors [19].
Modiﬁable factors include attack frequency [17], obesity
[20], medication overuse [21], caffeine use/misuse [10, 22,
23], sleep disorders (e.g., snoring, obstructive sleep apnea,
insomnia, hypersomnia) [24, 25], stressful life events [26,
27], speciﬁc psychological patterns (e.g., depression, anx-
iety, and personality disorders) [28, 29], behavioral issues
[30, 31], and family history of mood disorders and sub-
stance use disorders (alcohol, drugs) [32].
Other risk factors currently being investigated include
low serum vitamin D levels [33], gastroesophageal reﬂux
disease [34], and proinﬂammatory and prothrombotic states
[14, 35].
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form of headache comes from wrong conducts, as absence
of referral to headache centers during the worsening period,
lack of education in avoiding trigger factors, and inade-
quate life-style rhythms (fasting, sleepiness). Also the
recommendations that drugs be taken as early as possible,
effective with speciﬁc medications like triptans, increases
the risk that patients will take more of the drug than is
necessary, thus increasing the risk of inducing medication
overuse.
Regarding medication overuse, the risk of progression
from EM to CM is increased by any use of barbiturates and
opioids, while triptans are not associated with the same
risk. NSAIDs are either protective or inducers depending
on the headache frequency (protective against transition at
low-to-moderate monthly headache days, associated with
increased risk of transition at high levels of monthly
headache days) [36].
Regarding opioids’ association with migraine progres-
sion, the effect is dose-dependent (critical dose of expo-
sure: 8 days/month), and more pronounced in men [9, 36].
Barbiturates are also found to induce migraine progression
with a dose-dependent effect (critical dose of exposure:
5 days/month) but more pronounced in women [9, 36].
Triptans, on the other hand, induce migraine progression
only in those with high migraine frequency at baseline
(\14 days/month), but not overall [9, 36]. NSAIDs protect
against migraine progression unless individuals have C10
headache days/month (when they become inducers, rather
than protective), while caffeine containing over-the-coun-
ter products increase risk of progression [9, 36].
The substances associated with the overuse have dra-
matically changed over the past 20 years. There was a
signiﬁcant decrease in the relative frequency of probable
ergotamine overuse headache and probable combination
analgesic overuse headache, while the frequency of opioids
overuse headache remained the same. Conversely, the
relative frequency increased signiﬁcantly for triptans and
for combinations of acute medications [37].
The complex chronic migraine/medication overuse
headache should be detoxiﬁed ﬁrst
MOH constitutes a plus of CM and it is hard to think about
its appearance not being related to CM itself, unless
patients attempt counterproductive stoicism. Since MOH
does not stand alone, it should be at least considered a
complication of CM and not just a simple form of sec-
ondary headache [38].
In MOH sufferers, the treatment of choice is drug
withdrawal, which is used by most specialized centers as
the primary therapy. The goal of this treatment is not only
to detoxify the patients and stop the chronic headache but
also to improve responsiveness to acute or prophylactic
drugs [39].
Discontinuation of the acute medication can result in
worsening of the headache, nausea, vomiting, arterial
hypotension, tachycardia, sleep disturbances, restlessness,
anxiety, nervousness and rebound headache. Seizures or
hallucinations, although rare, are observed in patients who
overuse barbiturates containing anti-migraine drugs. These
symptoms generally last between 2 and 10 days (average
3.5 days), but can persist for up to 4 weeks [40]. With-
drawal symptoms are usually relieved by further intake of
the overused medication, but this could also lead to per-
petuation of the overuse.
The withdrawal headache seems to be shorter in patients
who have taken triptans (mean 4.1 days) than in patients
who have overused ergotamine (mean 6.7 days) or NSA-
IDs (mean 9.5 days) [41].
A further step beyond drug interruption results upon
smoothing symptoms following interruption, through
pharmacological support. Treatments for the acute phase of
drug withdrawal vary considerably between studies. They
generally include ﬂuid replacement, analgesics when
strictly necessary for severe rebound headache, tranquill-
isers, neuroleptics and steroids.
Among all classes of drugs, corticosteroids certainly are
the most frequently employed. Oral prednisone constitutes
the most common treatment during detoxiﬁcation [40, 42,
43]. However, studies on the management of withdrawal
headache using prednisolone have produced mixed results
[44, 45].
Different methods have been suggested for successful
drug withdrawal: home treatment, hospitalization, with or
without the use of steroids, and with re-prophylaxes per-
formed immediately or at the end of the wash-out period.
Even the imparting of advice alone obtained effective drug
withdrawal in patients with simple and complicated med-
ication overuse headache [46].
Currently, there are no universally accepted standard-
ized therapeutic protocols and no speciﬁc guidelines for
controlled trials in MOH. An agreement has been reached
only for withdrawal from abuse as conditio sine qua non to
reinstate the natural course of CM or high-frequency
migraine [47].
Inpatient versus outpatient drug withdrawal
Between the different drugs withdrawal strategies, inpa-
tient withdrawal seems the most helpful, and should be
preferred in patients who take barbiturates, in those who
are not able to stop taking medications as outpatients and
also in those with high levels of depression [48]. Con-
versely, an outpatient treatment can be an alternative for
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single drug or analgesic not containing barbiturates, and
who do not have a high level of depression or anxiety
[44, 48–50].
A direct comparison between inpatient and outpatient
withdrawal treatment shows that both methods lead to a
signiﬁcant reduction of headache days/month and migraine
disability after 12 months, without superiority of one
method [51]. Since the outpatient withdrawal approach is
less expensive than the inpatient approach, and is as suc-
cessful in motivated patients, it is the preferred choice in
many cases [40, 43].
Another helpful alternative for drug withdrawal is
infusion therapy within a day-hospital setting, limiting
patient’s permanence in hospital at a maximum of 6 h
during the infusion therapy [51].
A withdrawal and detoxiﬁcation therapeutic regimen,
which utilized abrupt discontinuation of the overused drug
and a therapeutic protocol including i.v. hydration, dexa-
methasone, metoclopramide and benzodiazepines for
7–10 days, obtained satisfactory results at 6 months of
follow-up in a sample of patients suffering from probable
CM and probable MOH during admission in eight Italian
hospitals. In this case, prophylactic medication was started
immediately after admission [52].
Data suggest that the patients affected by CDH and
medication overuse beneﬁt from withdrawal therapy per-
formed during hospitalization (dexamethasone 4 mg i.v./
day for 1 week, diazepam 6 mg/day for 10 days) along
with prophylaxis [53].
Abrupt versus gradual withdrawal
Although there are no studies comparing gradual and
abrupt interruption, the widespread opinion of specialists
considers drug withdrawal to be more effective when done
abruptly because this is believed to achieve a fast resolu-
tion of the drug-induced pain-coping behavior [21, 40, 43,
49, 54].
Most drugs causing MOH can be stopped abruptly. This
is most particular to the overuse of triptans, ergots, para-
cetamol, aspirin and NSAIDs. However, due to the possi-
bility of severe withdrawal symptoms, gradual withdrawal
is appropriate with opioids, barbiturates and, in particular,
benzodiazepines [54]. As with drugs that produce a with-
drawal syndrome, gradual reduction in caffeine intake may
be preferable to abrupt withdrawal [55].
Risk of relapses
The treatment can be considered successful when clinical
improvement is conﬁrmed after at least 1 year of follow-up
after withdrawal.
Findings from the recent studies suggest that patients
have a greatest risk for relapse within the ﬁrst 12 months
but have a decreased risk of relapse when they have
avoided medication overuse for 12 months after with-
drawal therapy [56].
Relapse percentages during the ﬁrst year after with-
drawal range between 22 and 44% [52]. Other three studies
considering a longer observation period (9–35 months)
[50, 57, 58] recorded success rates of 60, 70 and 73%,
respectively. Studies with a longer follow-up period (4–6
years) found relapse rates between 40 and 60% [56, 59–61].
Reported risk factors for relapse include: male gender
[52]; TTH or a combination of migraine plus TTH, rather
than migraine alone [59]; frequency of primary headache
disorder [57]; longer duration of migraine with more than
eight headache days/month [59]; long duration of migraine
before medication overuse [62]; long duration of drug
overuse [62]; greater number of the previous preventive
treatments [59, 62]; intake of combined analgesic drugs
(e.g., combination of one or more NSAIDs with caffeine or
codeine) [52, 59]; use of codeine-containing drugs [63];
ergotamine or triptan withdrawal more than analgesic
withdrawal [57, 59]; using the causative medication again
after withdrawal therapy [44]; lower improvement after
drug withdrawal [62]; low sleep quality [63]; high body
pain as measured by the Short Form 36 (SF-36) question-
naire [63]; and disability score for chronic headache esti-
mated by Migraine Disability Assessment Score (MIDAS)
[57].
Chronic migraine re-prophylaxis after detoxiﬁcation
Although according to estimates about 25% of all migraine
sufferers should be offered preventive therapies, prophy-
lactic medications are still signiﬁcantly underutilized [64].
A preventive treatment should be considered for all
patients with C3 disabling attacks/month that fail to ade-
quately respond to acute medication, and migraines that
greatly interfere with activities of daily life despite
appropriate use of acute medications [65].
The primary goals of preventive migraine therapy are to
reduce the frequency and severity of attacks, to reduce
reliance upon acute medications, to reduce visits to the
emergency room or doctor’s surgery and to improve the
migraine patient’s quality of life [65].
A long-term preventive treatment should be encouraged
in those patients at risk for migraine chronicization, with
medication overuse or contraindication to acute therapies.
A study conducted in a large series to assess prospec-
tively the impact of prophylaxis on health-related quality
of life (HRQOL), using the SF-36 questionnaire, and
daily activities, using MIDAS, indicates that migraine
596 J Headache Pain (2011) 12:593–601
123prophylaxis has the potential to reduce the global burden of
migraine on individuals and society [66].
Topiramate and onabotulinumtoxinA:
two options, but one choice
Up to now, only topiramate and local injection of onabo-
tulinumtoxinA have shown efﬁcacy as therapeutic agents
for re-prophylaxis after detoxiﬁcation in patients with CM
with and without medication overuse.
The use of topiramate in preventing migraine’s chroni-
cization process or in reverting consolidated CM is well
known.
Topiramate proved to be effective in reducing migraine
headache days [67, 68] and able to reduce the risk of
transformation to a chronic form [69]. The most common
adverse events (AEs) during topiramate treatment are
paresthesias (8.0%), cognitive symptoms (7.3%), fatigue
(4.7%), insomnia (3.4%), nausea (2.3%), loss of appetite,
anxiety, and dizziness (2.1%) [70]. These side effects are
not known in association with onabotulinumtoxinA [71].
Two studies compared the efﬁcacy and safety of topi-
ramate and onabotulinumtoxinA prophylactic treatment in
patients with CM [72, 73]. Signiﬁcant within, but not
between-groups, improvements were observed for several
outcomes: treatment responder rate; mean change from
baseline in number of headache/migraine days/month;
headache/migraine-free days/month; days on headache
medication; average severity of headache/migraine epi-
sodes/month; clinical improvements in quality of life,
sleep, work and recreational activities; Headache Impact
Test (HIT); and MIDAS.
Although topiramate and onabotulinumtoxinA resulted
in similar efﬁcacy in these studies, the two treatments
resulted in different AE proﬁles. The overall discontinua-
tion rate was signiﬁcantly higher in the topiramate than in
the onabotulinumtoxinA group, with AEs being the pri-
mary reason for withdrawal in the topiramate group [72,
73]. The results of these studies are in accordance with
controlled trials in the CM population that have reported
discontinuation rates of 25–44.2% with topiramate
compared with 10–25% with onabotulinumtoxinA [67, 68,
74–76].
The safety proﬁle indicates that onabotulinumtoxinA is
safe and well tolerated in the CM population, with a few
patients discontinuing treatment due to AEs (1.4–3.8%)
[75–79].
Given the substantial AEs and adherence issues associ-
ated with available pharmacotherapies for CM, the rela-
tively mild AEs associated with onabotulinumtoxinA may
present an attractive treatment alternative.
Results of two randomized, double-blind, placebo-con-
trolled trials have provided further insight into which
patients, dosages, and injection protocol may yield the
best results from prophylactic onabotulinumtoxinA therapy
[75, 76].
These trials have been the guidance for the study design
and the injection paradigm of the Phase III Research
Evaluating Migraine Prophylaxis Therapy (PREEMPT)
clinical program. This consists in two phase 3, multicenter
double-blind, parallel-group, placebo-controlled studies
(PREEMPT 1 and 2) that evaluated the efﬁcacy of onab-
otulinumtoxinA (155–195 U) in 1,384 adult patients with
CM who have 50% or more headache days fulﬁlling
migraine or probable migraine criteria and have four or
more distinct headache episodes at baseline screening
[77–79].
Important end points (primary and secondary) were
reduction of frequency of headache days (primary in
PREEMPT 2 and pooled analysis; secondary in PREEMPT
1) and headache episodes (primary in PREEMPT 1; sec-
ondary in PREEMPT 2 and pooled analysis).
OnabotulinumtoxinA resulted signiﬁcantly more effec-
tive than placebo in terms of frequency reduction during
headache days in both PREEMPT 1 (P = 0.006) and
PREEMPT 2 (P\0.001) [78, 79]. Statistically signiﬁcant
improvement from baseline after onabotulinumtoxinA
compared with placebo treatment was seen for headache
episodes in PREEMPT 2 (P = 0.003) [79], but not in
PREEMPT 1 [78]. Pooled analysis demonstrated that
onabotulinumtoxinA treatment signiﬁcantly reduced mean
frequency of headache days (-8.4 onabotulinumtoxinA,
-6.6 placebo; P\0.001) and headache episodes (-5.2
onabotulinumtoxinA, -4.9 placebo; P = 0.009) [77].
Statistically signiﬁcant improvements with onabotuli-
numtoxinA were seen in a number of secondary outcome
measures, including: migraine days (P\0.001); reduc-
tions in moderate or severe headache days (P\0.001);
cumulative hours of headache on headache days
(P\0.001); headache episodes (P\0.009); migraine
episodes (P\0.004); acute medication use (P\0.001);
and proportion of patients with a severe disability
(P\0.001) [77]. In PREEMT, onabotulinumtoxinA was
also reported to be effective in a subgroup of patients with
medication overuse. Furthermore PREEMPT showed a
good safety proﬁle. AEs occurred in 62.4% of the onabo-
tulinumtoxinA group and 51.7% of the placebo group.
Most AEs were mild-to-moderate in severity, and a few
patients discontinued the trial due to AEs (onabotulinum-
toxinA, 3.8%; placebo, 1.2%). The only AE reported with
an incidence over 5% in the onabotulinumtoxinA
group were neck pain (8.7%) and muscular weakness
(5.5%) [77–79].
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all, they prove that patients with CM, even those who
overuse acute headache medication, are an appropriate
target group supporting the previous studies which identi-
ﬁed CM patients as the ones most likely to beneﬁt from
onabotulinumtoxinA treatment [75, 76]; second, these
studies provide an injection paradigm [combination of
Fixed Sites Fixed Doses (155 U) plus ‘‘eventually’’ Follow
The Pain (40 U) protocols] that can be used as a guide for a
correct administration of onabotulinumtoxinA [80].
Concluding debates on onabotulinumtoxinA and CM
Despite these data, PREEMPT trials received several crit-
ics, particularly regarding the diagnosis of CM (65% of
patients had medication overuse, which precludes the
diagnosis of CM according to the IHS), the high percentage
(35%) of patients that never before received any pharma-
cological prophylaxis, and the effectiveness of blinding
(sine onabotulinumtoxinA weakens muscles and changes
the facial expression while placebo does not) [81–83].
Even the injection protocol adopted received critics [84].
However, the phase of the protracted debate on the efﬁ-
cacy of onabotulinumtoxinA in CM patients must be con-
sidered ended. In 2010, on the basis of the results of
PREEMPT clinical program, ﬁrst the Medicines and
HealthcareProductsRegulatoryAgency(MHRA)intheUK,
and later the Federal Drug Administration (FDA) in USA,
approved onabotulinumtoxinA injection therapy for the
prevention of headaches in adults with chronic migraine.
Identify the right targeting: not all patients are
the same
Patient selection appears to be a key to the successful use
of the toxin in headache management.
The pharmacologic proﬁle of onabotulinumtoxinA
makes it an appealing candidate for CM patient’s proﬁle.
Its long duration of action (3 months on average) and
favorable adverse effect proﬁle makes it particularly
attractive for patients with poor compliance, adherence, or
AE proﬁle with oral preventive medications [85].
Overall, several studies show a more favorable response
to onabotulinumtoxinA in: CM patients with unilateral
headache, scalp allodynia, and pericranial muscle tender-
ness [86, 87]; CDH patients with a shorter disease duration
(\30 years) [88]; CDH patients who did not overuse pain
medications than those who did [86]; patients who do not
respond effectively to any of the preventative treatments
(chronic refractory migraine) [86].
Furthermore onabotulinumtoxinA prophylactic therapy
markedly decreases costs related to acute headache
medication use suggesting onabotulinumtoxinA as a cost-
reasonable option for medication offsets alone especially in
patients with chronic headache with higher acute medica-
tion use [89, 90].
Keys to ideal management
Despite MOH is a disorder characterized by very own
features outlining a peculiar and autonomous disease, it
should be more correctly considered a complication of CM,
if not even in some cases its natural evolution.
The ﬁrst steps in the management of CM complicated by
medication overuse must be the withdrawal of the overused
drugs and a detoxiﬁcation treatment; that in order to stop
the chronic headache and mostly to improve the answer to
the second step of the management. It is represented by re-
prophylaxis with preventive medications that must be
started immediately after the detoxiﬁcation.
For its safety proﬁle and proven efﬁcacy onabotuli-
numtoxinA is the best therapeutic option and the ﬁrst
preventive medication to choose in CM patients, also in
those already underwent to detoxiﬁcation for medication
overuse.
Decades of research on the individual clinical features of
CDH sufferers, and on their response to the medications
currently available, have demonstrated the existence of a
subgroup of patients with a CDH which appeared to be
‘‘resistant’’ to treatment.
Even if ‘‘resistant CDH’’ is far from adding to the inter-
national classiﬁcation of headache disorders, physicians
should think of this when they face a migraine patient.
This is especially true for whom working in headache
clinics or centers of tertiary care, which are turning more
often in patients with severe forms of CM.
Thus, the future in the treatment and relapse prevention
of CM complicated by MOH, and mostly of ‘‘resistant
CDH’’, consists in considering how drugs currently used,
such as triptans and emerging therapies, present respon-
sivity proﬁles related to well-deﬁned genetic polymor-
phisms [19, 91, 92]. The feasible diagnostic setting for a
tailored treatment of CM based on the application of
pharmacogenomics will allow us to predetermine the efﬁ-
cacy of single old and new drugs by avoiding abuse and
chronicization due to non-responsivity of the abused drug.
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